David Molyneux, a professor at the the Liverpool School of Tropical Medicine, Liverpool, England, outlines how priorities on dealing with the big 3 infectious diseases -- HIV/AIDS, tuberculosis, and malaria -- is obstructing public health initiatives to tackle preventable diseases such as the viral, bacterial, and parasitic infections of the tropics, and acute respiratory infections and diarrheal diseases of children. Examples are given of numerous cost-effective treatment programs for diseases such as onchocerciasis (river blindness) and Chagas disease.
Molyneux comments, The emphasis on the 'Big Three' killers and the derogatory assignment to the category of other diseases of those that can so easily be controlled or even eliminated, neglects the proven success of a range of interventions. An investment of a fraction of the annual requirements of the global fund would bring long-lasting benefit to the millions that still remain disabled, reduce morbidity, and prevent disablement in future generations. If we are to ensure the efficient use of the substantial resources needed to reduce morbidity and mortality associated with HIV/AIDS, tuberculosis, and malaria, then a small investment in proven, cost-effective interventions against other diseases -- preferably from the global fund resources -- will bring sustainable public-health benefits, integrate well with and strengthen the health system, reduce disabling conditions, and bring collateral benefits to the health of the poorest nations.
He concludes, Policy makers are ignoring scientific and operational evidence that interventions against other diseases are effective. By concentrating on so few agents, current policies could perpetuate inequity, disrupt health financing policies, divert human resources from achievable goals, and deny opportunities for impoverished health systems to improve. Current policy also raises ethical issues. Resources are being transferred to interventions against the 'Big Three' that, realistically, have only a limited chance of success as they are reactive and do not adequately control transmission -- a pre-requisite for any public-health impact.
Source: Liverpool School of Tropical Medicine
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.